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INTRODUCTION
Hepatitis C is a common disease with an increasing incidence 
in the US. It is closely associated with type II mixed 
cryoglobulinemia (MC) and its complication of cryoglobulinemic 
vasculitis (CryoVas). HCV-associated cryoglobulinemic 
glomerulonephritis (HCV-CryoGN) occurs in 10-35% of those 
with CryoVas.
CASE PRESENTATION
• A 59-year-old female presented with AKI & proteinuria. In 2011 
she was diagnosed with HCV-CryoGN. Complete remission 
was achieved with IV Cyclophosphamide and steroids. SCr 
stabilized at 1.4 mg/dL and proteinuria of 0.3 g/g. In 2013 she 
was treated with DAAs for HCV and attained SVR.
• In September 2017, urinalysis showed proteinuria UPCR 3.5 
g/g and microhematuria. Labs revealed SCr 2.5mg/dL, elevated 
rheumatoid factor (RF) titers 334 IU/L with positive cryoglobulin 
screen for type II MC.
• Serologic work up for ANA, ANCA and anti-GBM Ab were all 




IgM(+2),C3(+2) & IgG(trace). Electron microscopy noted 
segmental sub-endothelial and mesangial deposits.
• Treated with rituximab (RTX) and prednisone, followed by RTX 
maintenance therapy. Treatment gradually improved the renal 
function, proteinuria, and RF levels.
DISCUSSION
Reports of HCV-CryoGN despite SVR after DAA therapy are 
rare. DAAs lead to SVR in the overwhelming majority of HCV 
patients, but are less consistent in treating CryoVas. A 
pathological explanation is mixed cryoglobulinemia syndrome is 
an immune-mediated process that becomes independent from 
the triggering virus.  Rituximab treatment has been found to 
deplete bone marrow B-cell clonal expansion resulting in a 
decrease of serum cryoglobulin and RF, correlating with 
improved treatment success rates with few adverse events.
CONCLUSION
HCV-CryoGN can occur in the absence of ongoing viral 
replication due to persistence of RF-producing memory B-cell 
clones.	Combining	the	efficacy	of	DAAs	in	eradicating	HCV	
infection	along	with	the	immunomodulatory	effect	of	RTX	can	
lead to improved treatment of HCV-CryoVas.
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